Bronchiectasis is a chronic respiratory condition characterized by permanent, abnormal dilation of the bronchi due to destructive inflammation and impaired mucociliary clearance. Management focuses on airway clearance, infection control, and inflammation reduction to prevent disease progression and improve quality of life.
🎯 Understanding Bronchiectasis
Key pathological features and clinical presentation:
Pathophysiology & Causes
Definition: Permanent bronchial dilation from chronic infection/inflammation
Vicious cycle: Infection → Inflammation → Airway damage → Impaired clearance → More infection
Common causes: Post-infectious, cystic fibrosis, immunodeficiency, ciliary dyskinesia
Clinical features: Chronic productive cough, recurrent infections, hemoptysis
Diagnosis & Assessment
Gold standard: High-resolution CT chest showing bronchial dilation
Sputum culture: Essential for identifying colonizing organisms
Severity scores: Bronchiectasis Severity Index (BSI), FACED score
Etiology workup: Immunoglobulins, CF sweat test, ciliary function tests
💊 Comprehensive Management Strategy
Multimodal approach targeting key pathological processes:
Airway Clearance & Mucolytics
- Goal: Enhance mucus clearance and reduce colonization
- Mucolytics: DNase, hypertonic saline, mannitol
- Bronchodilators: Facilitate deeper airway penetration
- Physical techniques: Chest physiotherapy, flutter devices
- Key Point: Foundation of daily management
Anti-infective Strategies
- Goal: Eradicate pathogens and prevent exacerbations
- Antibiotics: Targeted, inhaled, long-term suppression
- Monitoring: Regular sputum cultures and sensitivity
- Vaccinations: Prevent respiratory infections
- Key Point: Tailored to colonizing organisms
💊 Airway Clearance & Mucolytic Therapy
Medications to improve mucus clearance and reduce viscosity:
DNase (Dornase Alfa)
- Mechanism: Cleaves extracellular DNA in purulent sputum
- Indications: CF-related bronchiectasis, selected non-CF cases
- Dosing: 2.5 mg once daily via nebulizer
- Benefits: Reduces exacerbations, improves lung function
- Side Effects: Voice alteration, pharyngitis, chest pain
- Key Point: Most effective in CF bronchiectasis
Hypertonic Saline
- Mechanism: Osmotically draws water into airway lumen
- Concentration: 3-7% via nebulizer
- Dosing: 4-10 mL twice daily before airway clearance
- Benefits: Improves mucus clearance, reduces exacerbations
- Side Effects: Bronchospasm (pretreat with bronchodilator)
- Evidence: Strong for both CF and non-CF bronchiectasis
Mannitol Inhalation
- Mechanism: Osmotic agent that hydrates airway surface
- Formulation: Dry powder inhaler (Bronchitol)
- Dosing: 400 mg twice daily
- Benefits: Impro mucus clearance, quality of life
- Side Effects: Cough, throat irritation, bronchospasm
- Indications: CF bronchiectasis in adults
Conventional Mucolytics
- Examples: N-acetylcysteine, Erdosteine, Carbocisteine
- Mechanism: Break disulfide bonds in mucus glycoproteins
- Evidence: Limited for bronchiectasis specifically
- Use: May help with thick, tenacious secretions
- Side Effects: GI upset, rash, headache
- Key Point: Less evidence than hypertonic saline/DNase
🦠 Anti-infective Therapy
Strategic antibiotic use for infection control and prevention:
Inhaled Antibiotics
- Examples: Tobramycin, Colistin, Aztreonam
- Indications: Chronic Pseudomonas aeruginosa colonization
- Benefits: High local concentrations, minimal systemic effects
- Dosing: Typically twice daily via nebulizer
- Side Effects: Bronchospasm, cough, voice changes
- Key Point: First-line for chronic Pseudomonas infection
Macrolide Antibiotics
- Examples: Azithromycin, Erythromycin, Clarithromycin
- Mechanism: Anti-inflammatory and immunomodulatory effects
- Dosing: Azithromycin 250-500 mg 3x/week or daily
- Benefits: Reduce exacerbations, improve quality of life
- Monitoring: Hearing, liver function, QT interval
- Key Point: Long-term use for immunomodulation
Exacerbation Treatment
- Duration: 10-14 days typically
- Selection: Based on recent sputum culture results
- Common regimens: Amoxicillin-clavulanate, Doxycycline, Levofloxacin
- IV therapy: For severe exacerbations or resistant organisms
- Monitoring: Clinical response, side effects
- Key Point: Always culture sputum before starting antibiotics
Long-term Suppressive Therapy
- Indications: ≥3 exacerbations per year despite optimal care
- Options: Rotating oral antibiotics, continuous macrolides
- Monitoring: Sputum culture, drug toxicity, resistance
- Duration: Typically 3-6 month trials with reassessment
- Risks: Antibiotic resistance, side effects, cost
- Key Point: Individualize based on exacerbation frequency
📊 Antibiotic Selection Guide
| Organism | First-line Therapy | Alternative Options | Duration | Special Considerations |
|---|---|---|---|---|
| Pseudomonas aeruginosa | IV Anti-pseudomonal β-lactam + Aminoglycoside | Ciprofloxacin, Colistin, Aztreonam | 14 days | Consider dual therapy, inhaled antibiotics for chronic suppression |
| Haemophilus influenzae | Amoxicillin-clavulanate | Doxycycline, Respiratory fluoroquinolones | 7-10 days | Common in non-CF bronchiectasis, often β-lactamase producers |
| Staphylococcus aureus | Flucloxacillin | Clindamycin, Doxycycline, Co-trimoxazole | 7-14 days | Consider MRSA if risk factors present, check sensitivities |
| Mycobacterium avium complex | Clarithromycin + Ethambutol + Rifampin | Amikacin, Moxifloxacin | 12-18 months | Requires specialist management, monitor for toxicity |
| No predominant organism | Amoxicillin-clavulanate | Doxycycline, Levofloxacin | 7-10 days | Empirical therapy while awaiting culture results |
🌿 Anti-inflammatory & Adjunctive Therapy
Medications to control inflammation and manage symptoms:
Immunomodulatory Therapy
Macrolides: Azithromycin 250 mg daily or 500 mg 3x/week
Mechanism: Reduce neutrophil chemotaxis, decrease inflammation
Evidence: Reduces exacerbations in both CF and non-CF bronchiectasis
Monitoring: Hearing tests, liver function, ECG for QT prolongation
Duration: Long-term with periodic reassessment
Bronchodilators & Other Therapies
Bronchodilators: SABA before airway clearance if bronchospasm
ICS: Limited role unless asthma/COPD coexistence
Mucolytics: Continue during exacerbations
Nutrition: Address malnutrition common in severe disease
Oxygen: For chronic hypoxemia
- Screen for non-tuberculous mycobacteria before starting
- Monitor for hearing loss, tinnitus, and vestibular toxicity
- Check baseline ECG and monitor for QT prolongation
- Assess liver function regularly
- Be aware of significant drug interactions (statins, warfarin)
- Consider antibiotic resistance development with long-term use
🏥 Non-Pharmacological Management
Essential physical and supportive therapies:
Airway Clearance Techniques
Active cycle breathing: Breathing control, thoracic expansion, forced expiration
PEP devices: Positive expiratory pressure (flutter, acapella)
Postural drainage: Positioning to drain specific lung segments
High-frequency chest wall oscillation: Vest therapy
Exercise: Improves clearance and overall fitness
Frequency: Daily, sometimes twice daily during exacerbations
Comprehensive Care
Pulmonary rehabilitation: Exercise training, education, nutrition
Vaccinations: Influenza annually, pneumococcal as indicated
Nutrition: High-calorie, high-protein diet for weight maintenance
Psychological support: Address anxiety, depression common in chronic disease
Surgical options: Resection for localized disease, massive hemoptysis
Transplantation: For end-stage disease in selected patients
⚠️ Monitoring & Complications
Essential monitoring parameters and complication management:
Routine Monitoring
Symptoms: Cough, sputum volume/color, dyspnea scores
Sputum cultures: Quarterly or with clinical changes
Lung function: Spirometry 1-2 times yearly
Radiology: CT chest only if clinical deterioration
Quality of life: QOL-B or SGRQ questionnaires
Drug monitoring: Based on specific medications used
Complication Management
Hemoptysis: Mild - conservative; Massive - emergency intervention
Respiratory failure: Oxygen, ventilation support, transplantation evaluation
Cor pulmonale: Diuretics, oxygen, manage underlying hypoxia
Amyloidosis: Rare complication of chronic inflammation
Aspergilloma: Surgical resection or bronchial artery embolization
- Definition: >200-600 mL/24h or causing hemodynamic instability
- Immediate: ABCs, oxygen, IV access, crossmatch blood
- Positioning: Bleeding side down if known
- Consultations: Interventional radiology, thoracic surgery
- Bronchial artery embolization: First-line intervention
- Surgery: Reserved for embolization failure or life-threatening cases
🎯 Clinical Pearls
Essential considerations for bronchiectasis management:
- Airway clearance is fundamental - individualize techniques to patient preference
- Always obtain sputum culture before starting antibiotics for exacerbations
- Consider long-term macrolides for patients with frequent exacerbations
- Use inhaled antibiotics for chronic Pseudomonas aeruginosa infection
- Screen for and treat underlying causes when possible
- Pulmonary rehabilitation benefits all symptomatic patients
- Monitor for complications including hemoptysis and respiratory failure
- Teach proper airway clearance techniques and importance of adherence
- Educate about early recognition of exacerbations and action plan
- Demonstrate proper inhaler and nebulizer technique
- Discuss infection prevention strategies and vaccination importance
- Provide nutritional guidance for maintaining optimal weight
- Encourage physical activity within individual capacity
- Discuss advance care planning and palliative care options
🧠 Key Takeaways
- ✅ Airway clearance is cornerstone - daily techniques essential for all patients
- ✅ Targeted antibiotic therapy - base on sputum culture results
- ✅ Consider long-term macrolides - for patients with frequent exacerbations
- ✅ Inhaled antibiotics first-line - for chronic Pseudomonas infection
- ✅ Mucolytics enhance clearance - hypertonic saline and DNase most evidence-based
- ✅ Comprehensive approach needed - address nutrition, exercise, psychology
- ✅ Regular monitoring essential - symptoms, sputum cultures, lung function